Transcatheter mitral valve replacement with Mi‐thos system: First‐in‐human experience

Author:

Yang Ye1,Chen Jinmiao1ORCID,Dong Lili2,Lu Yuntao1,Lv Minzhi3,Guo Kefang4,Bagaber Ghufran5,Yang Jian6ORCID,Wang Chunsheng1,Wei Lai1

Affiliation:

1. Department of Cardiovascular Surgery, Zhongshan Hospital Fudan University Shanghai China

2. Department of Echocardiography, Zhongshan Hospital Fudan University Shanghai China

3. Department of Biostatistics, Zhongshan Hospital Fudan University Shanghai China

4. Department of Anesthesiology, Zhongshan Hospital Fudan University Shanghai China

5. Shanghai Medical College Fudan University Shanghai China

6. Department of Cardiovascular Surgery, Xijing Hospital Air Force Medical University Xi'an China

Abstract

AbstractBackgroundTranscatheter mitral valve replacement (TMVR) has become an alternative for high‐risk patients with severe mitral regurgitation (MR). The aim of this study was to evaluate the safety and feasibility of the Mi‐thos TMVR system (NewMed Medical) for high‐risk patients with severe MR.MethodsThis was a prospective, two‐center, single‐arm early feasibility study. Baseline characteristics, procedural data and 30‐day follow‐up outcomes were collected and analyzed. The primary endpoint was intraoperative success rate of device implantation. The second endpoints were all‐cause mortality and major post‐procedural complications. Echocardiographic data were evaluated by an independent core laboratory. Clinical events were adjudicated by a clinical events committee.ResultsTen high‐risk patients with severe MR were enrolled at two sites from August 2021 to November 2022. The median age was 70.5 years, and 60% of patients were female. The median Society of Thoracic Surgeons Predicted Risk of Mortality was 9.5%. The Mi‐thos TMVR system was successfully implanted via transapical access in all patients. There was no pericedural mortality or major postpericedural complications during the 30‐day follow‐up. All implanted prosthetic valves had no or trace valvular or paravalvular MR, and the median mitral valve gradient at 30 days was 2.0 mmHg (IQR: 2.0–3.0 mmHg). There was one mild left ventricular outflow tract obstruction.ConclusionsThe favorable short‐term outcomes of the Mi‐thos TMVR system demonstrated that it might be a feasible and safe therapeutic alternative for high‐risk patients with severe MR. Nevertheless, further evaluation of the Mi‐thos TMVR system is warranted.

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3